SCHEMBL1129010

SCHEMBL1129010

N[N+]12C=CN=CC1=C(C1CC(CN3CCCC3)C1)N=C2c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 5/20 0.45
APP P05067 1/20 0.38
LTA4H P09960 2/20 0.34
IGF1R P08069 4/20 0.33
INSR P06213 3/20 0.33
ROCK2 O75116 2/20 0.33
LYN P07948 2/20 0.33
FGFR1 P11362 2/20 0.33
RPS6KB1 P23443 2/20 0.33
FLT4 P35916 2/20 0.33
FLT3 P36888 2/20 0.33
STK3 Q13188 2/20 0.33
ROCK1 Q13464 2/20 0.33
ERBB4 Q15303 2/20 0.33
AURKB Q96GD4 2/20 0.33
PRKD2 Q9BZL6 2/20 0.33
PRKD3 O94806 1/20 0.33
RET P07949 1/20 0.33
FRK P42685 1/20 0.33
PTK6 Q13882 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129227 0.89 TNK2 (0.41) TNK2
SCHEMBL1129029 0.86 TNK2 (0.40) TNK2MMP9BTK
SCHEMBL401887 0.85 IGF1R (0.37) TNK2APPIGF1RINSRROCK2
SCHEMBL1128748 0.85 TNK2 (0.41) TNK2LCKKDR
SCHEMBL1129185 0.84 TNK2 (0.47) TNK2KDM2BMMP2MMP9BTK
SCHEMBL2457334 0.84 IGF1R (0.50) TNK2IGF1RINSRROCK2LYN
SCHEMBL1129001 0.83 TNK2 (0.43) TNK2IGF1RBTK
SCHEMBL2464388 0.83 IGF1R (0.51) TNK2IGF1RINSRROCK2LYN
SCHEMBL2462763 0.83 IGF1R (0.51) TNK2IGF1RINSRROCK2LYN
SCHEMBL1128841 0.83 TNK2 (0.38) TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TNK2 2837/4885APP 2130/4885LTA4H 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.